<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Chatterjee BK</submitter><funding>NIGMS NIH HHS</funding><pubmed_abstract>The AMP transferase, FICD, is an emerging drug target finetuning stress signaling in the endoplasmic reticulum (ER). FICD is a bi-functional enzyme, catalyzing both AMP addition (AMPylation) and removal (deAMPylation) from the ER resident chaperone BiP/GRP78. Despite increasing evidence linking excessive BiP/GRP78 AMPylation to human diseases, small molecules to inhibit pathogenic FICD variants are lacking. Using an &lt;i>in-vitro&lt;/i> high-throughput screen, we identify two small-molecule FICD inhibitors, C22 and C73. Both molecules significantly inhibit FICD-mediated BiP/GRP78 AMPylation in intact cells while only weakly inhibiting BiP/GRP78 deAMPylation. C22 and C73 also efficiently inhibit pathogenic FICD variants and improve proinsulin processing in β cells. Our study identifies and valid</pubmed_abstract><journal>bioRxiv : the preprint server for biology</journal><pagination>2024.07.13.603377</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11275912</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Small molecule FICD inhibitors suppress endogenous and pathologic FICD-mediated protein AMPylation.</pubmed_title><pmcid>PMC11275912</pmcid><funding_grant_id>R35 GM142561</funding_grant_id><pubmed_authors>Chakravorty A</pubmed_authors><pubmed_authors>Truttmann MC</pubmed_authors><pubmed_authors>Brooks CL</pubmed_authors><pubmed_authors>Lacy SM</pubmed_authors><pubmed_authors>Rech J</pubmed_authors><pubmed_authors>Arvan PD</pubmed_authors><pubmed_authors>Chatterjee BK</pubmed_authors><pubmed_authors>Alam M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Small molecule FICD inhibitors suppress endogenous and pathologic FICD-mediated protein AMPylation.</name><description>The AMP transferase, FICD, is an emerging drug target finetuning stress signaling in the endoplasmic reticulum (ER). FICD is a bi-functional enzyme, catalyzing both AMP addition (AMPylation) and removal (deAMPylation) from the ER resident chaperone BiP/GRP78. Despite increasing evidence linking excessive BiP/GRP78 AMPylation to human diseases, small molecules to inhibit pathogenic FICD variants are lacking. Using an &lt;i>in-vitro&lt;/i> high-throughput screen, we identify two small-molecule FICD inhibitors, C22 and C73. Both molecules significantly inhibit FICD-mediated BiP/GRP78 AMPylation in intact cells while only weakly inhibiting BiP/GRP78 deAMPylation. C22 and C73 also efficiently inhibit pathogenic FICD variants and improve proinsulin processing in β cells. Our study identifies and valid</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jul</publication><modification>2026-04-07T21:03:30.537Z</modification><creation>2025-04-04T02:46:38.481Z</creation></dates><accession>S-EPMC11275912</accession><cross_references><pubmed>39071275</pubmed><doi>10.1101/2024.07.13.603377</doi></cross_references></HashMap>